Literature DB >> 9707338

Mechanisms and prevention of secondary brain damage during intensive care.

N M Dearden1.   

Abstract

The injured brain may be damaged by primary impact, secondary injury from secondary damage due to initiation of destructive inflammatory and biochemical cascades by the primary injury or secondary ischemic injury following secondary insults that initiate or augment these immunological and biochemical cascades. Cerebral ischemia will arise whenever delivery of oxygen and substrates to the brain fall below metabolic needs. Many factors lead to the development of secondary insults to the injured brain during initial resuscitation, transport, surgery, and subsequent intensive care. Continuous monitoring of cerebral oxygenation (jugular oximetry, brain tissue PO2) and cerebral blood flow velocity (transcranial Doppler ultrasonography) in patients with brain trauma reveals multiple episodes of transient hypoperfusion with an adverse relationship between incidence and outcome. Secondary brain insults arise through systemic or intracranial mechanisms that reduce cerebral blood flow from compromised CPP, vascular distortion or cerebrovascular narrowing or lower oxygen delivery from hypoxemia associated with airway obstruction, pulmonary pathology, or anemia. Secondary brain ischemia remains a common pathway to secondary brain damage in most critically ill neurosurgical patients. In the future prevention of secondary brain injury may well hinge on giving a cocktail of novel agents that modify destructive biochemical and inflammatory pathways, each having a potential therapeutic window possibly in a subgroup of patients. To date, phase 3 clinical trials of several agents including PEGSOD and tyrilizad mesylate have failed to show relevant efficacy after brain trauma or subarachnoid hemorrhage. The therapeutic role of calcium channel blockers in traumatic subarachnoid hemorrhage is currently under investigation following the results of subgroup metaanalysis. Several phase 3, NMDA receptor antagonist studies are underway in brain trauma with results expected soon. Although we know that secondary insults promote excitotoxic secondary brain damage there is currently no pharmacological intervention with proven efficacy and, therefore, detection and correction of secondary insults appear to offer the best therapeutic strategy. After brain trauma, systemic hypotension, compromised CPP, raised ICP, elevated temperature, hypoxemia, and jugular bulb venous desaturation are associated with poor prognosis. Clinical trials of moderate hypothermia following brain trauma are ongoing. Following adult brain trauma maintenance of CPP above at least 65 mmHg (probably > 40 mmHg in children below 8 years) seems important to improve outcome indicating the need for continuous ICP monitoring during intensive care of brain-injured patients.

Entities:  

Mesh:

Year:  1998        PMID: 9707338

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  13 in total

1.  Influence of definition and location of hypotension on outcome following severe pediatric traumatic brain injury.

Authors:  Bria M Coates; Monica S Vavilala; Christopher D Mack; Saipin Muangman; Pilar Suz; Sam R Sharar; Eileen Bulger; Arthur M Lam
Journal:  Crit Care Med       Date:  2005-11       Impact factor: 7.598

Review 2.  Airway management in neurological emergencies.

Authors:  Lynn P Roppolo; Karina Walters
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Real-time quantitative monitoring of cerebral blood flow by laser speckle contrast imaging after cardiac arrest with targeted temperature management.

Authors:  Junyun He; Hongyang Lu; Leanne Young; Ruoxian Deng; Daniel Callow; Shanbao Tong; Xiaofeng Jia
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-28       Impact factor: 6.200

4.  Critical thresholds of intracranial pressure and cerebral perfusion pressure related to age in paediatric head injury.

Authors:  I R Chambers; P A Jones; T Y M Lo; R J Forsyth; B Fulton; P J D Andrews; A D Mendelow; R A Minns
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08-15       Impact factor: 10.154

5.  [Secondary decompression trepanation in progressive post-traumatic brain edema after primary decompressive craniotomy].

Authors:  T Mussack; E Wiedemann; T Hummel; P Biberthaler; K G Kanz; W Mutschler
Journal:  Unfallchirurg       Date:  2003-10       Impact factor: 1.000

6.  Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury.

Authors:  Georgene W Hergenroeder; Anthony N Moore; J Philip McCoy; Leigh Samsel; Norman H Ward; Guy L Clifton; Pramod K Dash
Journal:  J Neuroinflammation       Date:  2010-03-11       Impact factor: 8.322

7.  pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH.

Authors:  Haichen Wang; Michael L James; Talaignair N Venkatraman; Lawrence J Wilson; Polina Lyuboslavsky; Scott J Myers; Christopher D Lascola; Daniel T Laskowitz
Journal:  Neurocrit Care       Date:  2014-02       Impact factor: 3.210

8.  Impact of platelet transfusion on survival of patients with intracerebral hemorrhage after administration of anti-platelet agents at a tertiary emergency center.

Authors:  Yuhko Suzuki; Takao Kitahara; Kazui Soma; Shingo Konno; Kimitoshi Sato; Sachio Suzuki; Hidehiro Oka; Masaru Yamada; Kiyotaka Fujii; Yukio Kitahara; Yuji Yamamoto; Takashi Otsuka; Yoshihiro Sugiura; Yuhsaku Kanoh; Yoshiko Tamai; Hitoshi Ohto
Journal:  PLoS One       Date:  2014-05-28       Impact factor: 3.240

9.  Computed Tomography Profile and its Utilization in Head Injury Patients in Emergency Department: A Prospective Observational Study.

Authors:  Archana Waganekar; Jagadish Sadasivan; A Sathia Prabhu; K T Harichandrakumar
Journal:  J Emerg Trauma Shock       Date:  2018 Jan-Mar

10.  High-Dose Intravenous Ascorbic Acid: Ready for Prime Time in Traumatic Brain Injury?

Authors:  Stefan W Leichtle; Anand K Sarma; Micheal Strein; Vishal Yajnik; Dennis Rivet; Adam Sima; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.